Essex Investment Management Co. LLC decreased its stake in Harvard Bioscience Inc. (NASDAQ:HBIO) by 1.1% during the second quarter, Holdings Channel reports. The fund owned 162,208 shares of the company’s stock after selling 1,787 shares during the period. Essex Investment Management Co. LLC’s holdings in Harvard Bioscience were worth $464,000 at the end of the most recent reporting period.
A number of other institutional investors have also added to or reduced their stakes in HBIO. First Manhattan Co. acquired a new position in Harvard Bioscience during the second quarter valued at about $125,000. Geode Capital Management LLC raised its stake in shares of Harvard Bioscience by 1.4% in the first quarter. Geode Capital Management LLC now owns 168,634 shares of the company’s stock valued at $509,000 after buying an additional 2,254 shares during the period. State Street Corp raised its stake in shares of Harvard Bioscience by 5.7% in the first quarter. State Street Corp now owns 316,644 shares of the company’s stock valued at $955,000 after buying an additional 17,018 shares during the period. Foundry Partners LLC raised its stake in shares of Harvard Bioscience by 0.3% in the second quarter. Foundry Partners LLC now owns 505,925 shares of the company’s stock valued at $1,447,000 after buying an additional 1,475 shares during the period. Finally, Acadian Asset Management LLC raised its stake in shares of Harvard Bioscience by 3.1% in the second quarter. Acadian Asset Management LLC now owns 729,779 shares of the company’s stock valued at $2,088,000 after buying an additional 21,961 shares during the period. Institutional investors own 66.31% of the company’s stock.
Shares of Harvard Bioscience Inc. (NASDAQ:HBIO) traded down 7.58% during midday trading on Friday, hitting $2.44. The stock had a trading volume of 638,836 shares. The company’s market cap is $83.72 million. The firm has a 50 day moving average of $2.69 and a 200-day moving average of $2.96. Harvard Bioscience Inc. has a one year low of $2.41 and a one year high of $4.02.
Harvard Bioscience (NASDAQ:HBIO) last issued its earnings results on Thursday, July 28th. The company reported $0.03 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $0.03. Harvard Bioscience had a negative net margin of 18.04% and a positive return on equity of 3.40%. The firm had revenue of $26.10 million for the quarter, compared to analysts’ expectations of $26.60 million. On average, analysts forecast that Harvard Bioscience Inc. will post $0.16 earnings per share for the current fiscal year.
Separately, Zacks Investment Research raised Harvard Bioscience from a “sell” rating to a “hold” rating in a research note on Tuesday, July 12th.
Harvard Bioscience Company Profile
Harvard Bioscience, Inc is a developer, manufacturer and marketer of a range of specialized products, apparatus and scientific instruments. The Company’s products are used to advance life science research at pharmaceutical and biotechnology companies, universities and government laboratories across the world.
Want to see what other hedge funds are holding HBIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Harvard Bioscience Inc. (NASDAQ:HBIO).
Receive News & Ratings for Harvard Bioscience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience Inc. and related companies with MarketBeat.com's FREE daily email newsletter.